Other Species / Isoforms
  GATAD2B (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
T5-p
___MDRMtEDALrLN
0 1
GATAD2B (human) ___MDRMtEDALrLN T5-p
GATAD2B (mouse) ___MDRMTEDALRLN T5
GATAD2B (rat) ___MDRMTEDALRLN T5
R10-m1
RMtEDALrLNLLKRs
0 5
GATAD2B (human) RMtEDALrLNLLKRs R10-m1
GATAD2B (mouse) RMTEDALRLNLLKRs R10
GATAD2B (rat) RMTEDALRLNLLKRS R10
S17-p
rLNLLKRsLDPADER
0 5
GATAD2B (human) rLNLLKRsLDPADER S17-p
GATAD2B (mouse) RLNLLKRsLDPADER S17-p
GATAD2B (rat) RLNLLKRSLDPADER S17
K30-ub
ERDDVLAkRLkMEGH
0 4
GATAD2B (human) ERDDVLAkRLkMEGH K30-ub
GATAD2B (mouse) ERDDVLAKRLKMEGH K30
GATAD2B (rat) ERDDVLAKRLKMEGH K30
K33-sm
DVLAkRLkMEGHEAM
Downstream
1 0
Effects on Modified Protein
  • molecular association, regulation
Effects on Biological Processes:
  • transcription, inhibited
GATAD2B (human) DVLAkRLkMEGHEAM K33-sm
GATAD2B (mouse) DVLAKRLKMEGHEAM K33
GATAD2B (rat) DVLAKRLKMEGHEAM K33
K44-ub
HEAMERLkMLALLKR
0 2
GATAD2B (human) HEAMERLkMLALLKR K44-ub
GATAD2B (mouse) HEAMERLKMLALLKR K44
GATAD2B (rat) HEAMERLKMLALLKR K44
K52
MLALLKRKDLANLEV
0 1
GATAD2B (human) MLALLKRKDLANLEV K52
GATAD2B (mouse) MLALLKRkDLANLEV K52-ac
GATAD2B (rat) MLALLKRKDLANLEV K52
K52-ub
MLALLKRkDLANLEV
0 1
GATAD2B (human) MLALLKRkDLANLEV K52-ub
GATAD2B (mouse) MLALLKRKDLANLEV K52
GATAD2B (rat) MLALLKRKDLANLEV K52
K66-ub
VPHELPTkQDGSGVK
0 1
GATAD2B (human) VPHELPTkQDGSGVK K66-ub
GATAD2B (mouse) VPHELPTKQDGSGVk K66
GATAD2B (rat) VPHELPTKQDGSGVK K66
K73
kQDGSGVKGYEEKLN
0 1
GATAD2B (human) kQDGSGVKGYEEKLN K73
GATAD2B (mouse) KQDGSGVkGYEEKLN K73-ac
GATAD2B (rat) KQDGSGVKSYEEKLN K73
K97-ub
RTAGRPGkENINDEP
0 2
GATAD2B (human) RTAGRPGkENINDEP K97-ub
GATAD2B (mouse) RTAGRPGKENINDEP K98
GATAD2B (rat) RTAGRPGKENINDEP K97
S112
VDMSARRSEPERGRL
0 3
GATAD2B (human) VDMSARRSEPERGRL S112
GATAD2B (mouse) VDMSARRsEPDRGRL S113-p
GATAD2B (rat) VDMSARRSEPDRGRL S112
T120-p
EPERGRLtPsPDIIV
Upstream
0 93
Regulatory protein:
  • PRP4 (human)
Treatment
  • antibody
  • lapatinib
  • nocodazole
GATAD2B (human) EPERGRLtPsPDIIV T120-p
GATAD2B (mouse) EPDRGRLtPsPDIIV T121-p
GATAD2B (rat) EPDRGRLtPsPDIIV T120-p
S122-p
ERGRLtPsPDIIVLs
Upstream
0 88
Regulatory protein:
  • PRP4 (human)
Treatment
  • antibody
  • lapatinib
  • nocodazole
GATAD2B (human) ERGRLtPsPDIIVLs S122-p
GATAD2B (mouse) DRGRLtPsPDIIVLs S123-p
GATAD2B (rat) DRGRLtPsPDIIVLs S122-p
S129-p
sPDIIVLsDNEAssP
Upstream
0 95
Treatment
  • antibody
  • lapatinib
  • nocodazole
GATAD2B (human) sPDIIVLsDNEAssP S129-p
GATAD2B (mouse) sPDIIVLsDNEAssP S130-p
GATAD2B (rat) sPDIIVLsDNEAssP S129-p
S134-p
VLsDNEAssPRSSsR
Upstream
0 21
Treatment
  • nocodazole
GATAD2B (human) VLsDNEAssPRSSsR S134-p
GATAD2B (mouse) VLsDNEAssPRSSsR S135-p
GATAD2B (rat) VLsDNEAssPRSSSR S134-p
S135-p
LsDNEAssPRSSsRM
Upstream
0 79
Treatment
  • nocodazole
GATAD2B (human) LsDNEAssPRSSsRM S135-p
GATAD2B (mouse) LsDNEAssPRSSsRM S136-p
GATAD2B (rat) LsDNEAssPRSSSRM S135-p
S140-p
AssPRSSsRMEERLk
0 3
GATAD2B (human) AssPRSSsRMEERLk S140-p
GATAD2B (mouse) AssPRSSsRMEERLK S141-p
GATAD2B (rat) AssPRSSSRMEERLK S140
K147-ac
sRMEERLkAANLEMF
0 2
GATAD2B (human) sRMEERLkAANLEMF K147-ac
GATAD2B (mouse) sRMEERLKAANLEMF K148
GATAD2B (rat) SRMEERLKAANLEMF K147
K147-ub
sRMEERLkAANLEMF
0 1
GATAD2B (human) sRMEERLkAANLEMF K147-ub
GATAD2B (mouse) sRMEERLKAANLEMF K148
GATAD2B (rat) SRMEERLKAANLEMF K147
S189
LLKKLRQSQLQkENV
0 1
GATAD2B (human) LLKKLRQSQLQkENV S189
GATAD2B (mouse) LLKKLRQsQLQkENV S190-p
GATAD2B (rat) LLKKLRQSQLQKENV S189
K193-ub
LRQSQLQkENVVQKt
0 4
GATAD2B (human) LRQSQLQkENVVQKt K193-ub
GATAD2B (mouse) LRQsQLQkENVVQkT K194-ub
GATAD2B (rat) LRQSQLQKENVVQKT K193
K199
QkENVVQKtPVVQNA
0 4
GATAD2B (human) QkENVVQKtPVVQNA K199
GATAD2B (mouse) QkENVVQkTPVVQNA K200-ub
GATAD2B (rat) QKENVVQKTPVVQNA K199
T200-p
kENVVQKtPVVQNAA
0 3
GATAD2B (human) kENVVQKtPVVQNAA T200-p
GATAD2B (mouse) kENVVQkTPVVQNAA T201
GATAD2B (rat) KENVVQKTPVVQNAA T200
S208-p
PVVQNAAsIVQPsPA
0 2
GATAD2B (human) PVVQNAAsIVQPsPA S208-p
GATAD2B (mouse) PVVQNAASIVQPsPA S209
GATAD2B (rat) PVVQNAASIVQPSPA S208
S213-p
AAsIVQPsPAHVGQQ
Upstream
0 6
Treatment
  • nocodazole
GATAD2B (human) AAsIVQPsPAHVGQQ S213-p
GATAD2B (mouse) AASIVQPsPAHVGQQ S214-p
GATAD2B (rat) AASIVQPSPAHVGQQ S213
S223-p
HVGQQGLsKLPsRPG
0 1
GATAD2B (human) HVGQQGLsKLPsRPG S223-p
GATAD2B (mouse) HVGQQGLSKLPSRPG S224
GATAD2B (rat) HVGQQGLSKLPSRPG S223
S227-p
QGLsKLPsRPGAQGV
0 5
GATAD2B (human) QGLsKLPsRPGAQGV S227-p
GATAD2B (mouse) QGLSKLPSRPGAQGI S228
GATAD2B (rat) QGLSKLPSRPGAQGI S227
R240-m1
GVEPQNLrTLQGHsV
0 2
GATAD2B (human) GVEPQNLrTLQGHsV R240-m1
GATAD2B (mouse) GIEPQNMRTLQGHSV R241
GATAD2B (rat) GIEPQNLRTLQGHSV R240
S246-p
LrTLQGHsVIrSATN
0 1
GATAD2B (human) LrTLQGHsVIrSATN S246-p
GATAD2B (mouse) MRTLQGHSVIRSATN S247
GATAD2B (rat) LRTLQGHSVIRSAAN S246
R249-m1
LQGHsVIrSATNTTL
0 1
GATAD2B (human) LQGHsVIrSATNTTL R249-m1
GATAD2B (mouse) LQGHSVIRSATNTTL R250
GATAD2B (rat) LQGHSVIRSAANTTL R249
R264-m1
PHMLMSQrVIAPNPA
0 1
GATAD2B (human) PHMLMSQrVIAPNPA R264-m1
GATAD2B (mouse) PHMLMSQRVIAPNPA R265
GATAD2B (rat) PHMLMSQRVIAPNPA R264
R277-m1
PAQLQGQrGPPkPGL
0 4
GATAD2B (human) PAQLQGQrGPPkPGL R277-m1
GATAD2B (mouse) PAQLQGQRGPPKPGI R278
GATAD2B (rat) PAQLQGQRGPPKPGI R277
K281-m1
QGQrGPPkPGLVrTT
0 1
GATAD2B (human) QGQrGPPkPGLVrTT K281-m1
GATAD2B (mouse) QGQRGPPKPGIVRTT K282
GATAD2B (rat) QGQRGPPKPGIVrTT K281
R286-m1
PPkPGLVrTTTPNMN
0 18
GATAD2B (human) PPkPGLVrTTTPNMN R286-m1
GATAD2B (mouse) PPKPGIVRTTTPNMN R287
GATAD2B (rat) PPKPGIVrTTTPNMN R286-m1
R286-m2
PPkPGLVrTTTPNMN
0 1
GATAD2B (human) PPkPGLVrTTTPNMN R286-m2
GATAD2B (mouse) PPKPGIVRTTTPNMN R287
GATAD2B (rat) PPKPGIVRTTTPNMN R286
T311-p
SSVPCQRtTSSAIyM
0 1
GATAD2B (human) SSVPCQRtTSSAIyM T311-p
GATAD2B (mouse) SSVPCQRTTSSAIyM T312
GATAD2B (rat) SSVPCQRTTSSAIYM T311
Y317-p
RtTSSAIyMNLASHI
0 69
GATAD2B (human) RtTSSAIyMNLASHI Y317-p
GATAD2B (mouse) RTTSSAIyMNLASHI Y318-p
GATAD2B (rat) RTTSSAIYMNLASHI Y317
R331-m1
IQPGTVNrVssPLPs
0 2
GATAD2B (human) IQPGTVNrVssPLPs R331-m1
GATAD2B (mouse) IQPGTVNRVssPLPs R332
GATAD2B (rat) IQPGTVNRVssPLPs R331
S333-p
PGTVNrVssPLPsPs
0 9
GATAD2B (human) PGTVNrVssPLPsPs S333-p
GATAD2B (mouse) PGTVNRVssPLPsPs S334-p
GATAD2B (rat) PGTVNRVssPLPsPS S333-p
S334-p
GTVNrVssPLPsPsA
0 21
GATAD2B (human) GTVNrVssPLPsPsA S334-p
GATAD2B (mouse) GTVNRVssPLPsPsA S335-p
GATAD2B (rat) GTVNRVssPLPsPSA S334-p
S338-p
rVssPLPsPsAMtDA
Upstream
0 31
Treatment
  • EGF
  • ischemia
  • nocodazole
  • selumetinib
  • vemurafenib
GATAD2B (human) rVssPLPsPsAMtDA S338-p
GATAD2B (mouse) RVssPLPsPsAMsDA S339-p
GATAD2B (rat) RVssPLPsPSAMSDA S338-p
S340-p
ssPLPsPsAMtDAAN
0 8
GATAD2B (human) ssPLPsPsAMtDAAN S340-p
GATAD2B (mouse) ssPLPsPsAMsDAAN S341-p
GATAD2B (rat) ssPLPsPSAMSDAAN S340
T343-p
LPsPsAMtDAANSQA
0 2
GATAD2B (human) LPsPsAMtDAANSQA T343-p
GATAD2B (mouse) LPsPsAMsDAANSQA S344-p
GATAD2B (rat) LPsPSAMSDAANSQA S343
K432-sm
TDFTPHWkQEKNGKI
0 1
GATAD2B (human) TDFTPHWkQEKNGKI K432-sm
GATAD2B (mouse) TDFTPHWKQEKNGKI K433
GATAD2B (rat) TDFTPHWKQEKNGKI K432
K454-ub
SNQKKALkAEHTNRL
0 1
GATAD2B (human) SNQKKALkAEHTNRL K454-ub
GATAD2B (mouse) SNQKKALKAEHTNRL K455
GATAD2B (rat) SNQKKALKAEHTNRL K454
K467-ub
RLKNAFVkALQQEQE
0 9
GATAD2B (human) RLKNAFVkALQQEQE K467-ub
GATAD2B (mouse) RLKNAFVkALQQEQE K468-ub
GATAD2B (rat) RLKNAFVKALQQEQE K467
S486-p
LQQQAALsPTtAPAV
Upstream
0 42
Treatment
  • BI2536
  • ischemia
  • nocodazole
GATAD2B (human) LQQQAALsPTtAPAV S486-p
GATAD2B (mouse) LQQQAALsPTTAPAV S487-p
GATAD2B (rat) LQQQAALsPTTAPAV S486-p
T489-p
QAALsPTtAPAVSsV
0 1
GATAD2B (human) QAALsPTtAPAVSsV T489-p
GATAD2B (mouse) QAALsPTTAPAVSSV T490
GATAD2B (rat) QAALsPTTAPAVSSV T489
S495-p
TtAPAVSsVSkQETI
Upstream
0 1
Treatment
  • BI2536
GATAD2B (human) TtAPAVSsVSkQETI S495-p
GATAD2B (mouse) TTAPAVSSVSKQETI S496
GATAD2B (rat) TTAPAVSSVSKQETI S495
K498-ub
PAVSsVSkQETIMRH
0 1
GATAD2B (human) PAVSsVSkQETIMRH K498-ub
GATAD2B (mouse) PAVSSVSKQETIMRH K499
GATAD2B (rat) PAVSSVSKQETIMRH K498
K498-sm
PAVSsVSkQETIMRH
0 1
GATAD2B (human) PAVSsVSkQETIMRH K498-sm
GATAD2B (mouse) PAVSSVSKQETIMRH K499
GATAD2B (rat) PAVSSVSKQETIMRH K498
R509-m1
IMRHHTLrQAPQPQS
0 3
GATAD2B (human) IMRHHTLrQAPQPQS R509-m1
GATAD2B (mouse) IMRHHTLRQAPQPQS R510
GATAD2B (rat) IMRHHTLRQAPQPQS R509
S517-p
QAPQPQSsLQrGIPT
0 1
GATAD2B (human) QAPQPQSsLQrGIPT S517-p
GATAD2B (mouse) QAPQPQSSLQRGIPT S518
GATAD2B (rat) QAPQPQSSLQRGIPT S517
R520-m1
QPQSsLQrGIPTSAr
0 3
GATAD2B (human) QPQSsLQrGIPTSAr R520-m1
GATAD2B (mouse) QPQSSLQRGIPTSAR R521
GATAD2B (rat) QPQSSLQRGIPTSAR R520
R527-m1
rGIPTSArSMLSNFA
0 7
GATAD2B (human) rGIPTSArSMLSNFA R527-m1
GATAD2B (mouse) RGIPTSARSMLSNFA R528
GATAD2B (rat) RGIPTSARSMLSNFA R527
S540-p
FAQAPQLsVPGGLLG
0 2
GATAD2B (human) FAQAPQLsVPGGLLG S540-p
GATAD2B (mouse) FAQAPQLSVPGGLLG S541
GATAD2B (rat) FAQAPQLSVPGGLLG S540
T558-p
VNIAYLNtGIGGHKG
0 2
GATAD2B (human) VNIAYLNtGIGGHKG T558-p
GATAD2B (mouse) VNIAYLNTGIGGHKA T559
GATAD2B (rat) VNIAYLNTGIGGHKA T558
R571-m1
KGPSLADrQREYLLD
0 1
GATAD2B (human) KGPSLADrQREYLLD R571-m1
GATAD2B (mouse) KAPSLADRQREYLLD R572
GATAD2B (rat) KAPSLADRQREYLLD R571
S584-gl
LDMIPPRsIsQSISG
Upstream
1 3
Treatment
  • PUGNAc
GATAD2B (human) LDMIPPRsIsQSISG S584-gl
GATAD2B (mouse) LDMIPPRsISQSISG S585-gl
GATAD2B (rat) LDMIPPRSISQSISG S584
S586-p
MIPPRsIsQSISGQk
0 2
GATAD2B (human) MIPPRsIsQSISGQk S586-p
GATAD2B (mouse) MIPPRsISQSISGQK S587
GATAD2B (rat) MIPPRSISQSISGQK S586
S586-gl
MIPPRsIsQSISGQk
Upstream
1 1
Treatment
  • PUGNAc
GATAD2B (human) MIPPRsIsQSISGQk S586-gl
GATAD2B (mouse) MIPPRsISQSISGQK S587
GATAD2B (rat) MIPPRSISQSISGQK S586
K593-ac
sQSISGQk_______
0 1
GATAD2B (human) sQSISGQk_______ K593-ac
GATAD2B (mouse) SQSISGQK_______ K594
GATAD2B (rat) SQSISGQK_______ K593
K593-ub
sQSISGQk_______
0 1
GATAD2B (human) sQSISGQk_______ K593-ub
GATAD2B (mouse) SQSISGQK_______ K594
GATAD2B (rat) SQSISGQK_______ K593